The role of natural killer cells in immunity against multiple myeloma

Multiple Myeloma

(2017) Kenneth C. Anderson et al.   Journal of the National Comprehensive Cancer Network

TGF-  Utilizes SMAD3 to Inhibit CD16-Mediated IFN-  Production and Antibody-Dependent Cellular Cytotoxicity in Human NK Cells

(2014) R. Trotta et al.   JOURNAL OF IMMUNOLOGY

Proteasome inhibitor lactacystin augments natural killer cell cytotoxicity of myeloma via downregulation of HLA class I

(2011) Xiaosong Wu et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

How "immunomodulatory" are IMIDs?

(2011) C. S. Mitsiades   BLOOD

IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect

(2011) D. M. Benson et al.   BLOOD

Monoclonal antibodies in the treatment of multiple myeloma

(2011) Paul G. Richardson et al.   BRITISH JOURNAL OF HAEMATOLOGY

Prostaglandin E2 (PGE2) suppresses natural killer cell function primarily through the PGE2 receptor EP4

(2011) Dawn Holt et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Novel Role for STAT3 in Transcriptional Regulation of NK Immune Cell Targeting Receptor MICA on Cancer Cells

(2011) R. Bedel et al.   CANCER RESEARCH

From Myeloma Precursor Disease to Multiple Myeloma: New Diagnostic Concepts and Opportunities for Early Intervention

(2011) Ola Landgren et al.   CLINICAL CANCER RESEARCH

Surface molecule CD229 as a novel target for the diagnosis and treatment of multiple myeloma

(2011) D. Atanackovic et al.   HAEMATOLOGICA

Impact of intracellular alpha fetoprotein on retinoic acid receptors-mediated expression of GADD153 in human hepatoma cell lines

(2011) Chaoying Li et al.   INTERNATIONAL JOURNAL OF CANCER

Donor KIR haplotype B improves progression-free and overall survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma

(2011) N Kröger et al.   LEUKEMIA

Crystal structure of human natural cytotoxicity receptor NKp30 and identification of its ligand binding site

(2011) M. G. Joyce et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Innate or Adaptive Immunity? The Example of Natural Killer Cells

(2011) E. Vivier et al.   SCIENCE

Interaction between KIR3DS1 and HLA-Bw4 predicts for progression-free survival after autologous stem cell transplantation in patients with multiple myeloma

(2010) I. H. Gabriel et al.   BLOOD

The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy

(2010) A. K. Hsu et al.   BLOOD

Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma

(2010) G. Gorgun et al.   BLOOD

The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody

(2010) D. M. Benson et al.   BLOOD

Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma

(2010) R. H. Prabhala et al.   BLOOD

Dexamethasone Synergizes with Lenalidomide to Inhibit Multiple Myeloma Tumor Growth, But Reduces Lenalidomide-Induced Immunomodulation of T and NK Cell Function

(2010) A. K. Gandhi et al.   CURRENT CANCER DRUG TARGETS

Natural killer cell activity in monoclonal gammopathies: Relation to disease activity

(2010) A. Österborg et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Progress in allogeneic transplantation for multiple myeloma

(2010) Gösta Gahrton   EUROPEAN JOURNAL OF HAEMATOLOGY

International Myeloma Working Group Consensus Statement Regarding the Current Status of Allogeneic Stem-Cell Transplantation for Multiple Myeloma

(2010) Henk Lokhorst et al.   JOURNAL OF CLINICAL ONCOLOGY

Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells

(2009) F. Romagne et al.   BLOOD

Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44+) and T (HLA-DR+) cells

(2009) M Lioznov et al.   BONE MARROW TRANSPLANTATION

CD4+CD25+FoxP3+regulatory T cells are increased whilst CD3+CD4−CD8−αβTCR+Double Negative T cells are decreased in the peripheral blood of patients with multiple myeloma which correlates with disease burden

(2009) Sylvia Feyler et al.   BRITISH JOURNAL OF HAEMATOLOGY

Reduced immune effector cell NKG2D expression and increased levels of soluble NKG2D ligands in multiple myeloma may not be causally linked

(2009) Marie von Lilienfeld-Toal et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Changes in activatory and inhibitory natural killer (NK) receptors may induce progression to multiple myeloma: Implications for tumor evasion of T and NK cells

(2009) Mónica Bernal et al.   HUMAN IMMUNOLOGY

Safety analysis ofex vivo-expanded NK and NK-like T cells administered to cancer patients: a Phase I clinical study

(2009) Lisbeth Barkholt et al.   Immunotherapy

Heat Shock Protein-90 Inhibitors Increase MHC Class I-Related Chain A and B Ligand Expression on Multiple Myeloma Cells and Their Ability to Trigger NK Cell Degranulation

(2009) C. Fionda et al.   JOURNAL OF IMMUNOLOGY

Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma

(2009) H Quach et al.   LEUKEMIA

Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma

(2009) F. van Rhee et al.   MOLECULAR CANCER THERAPEUTICS

Influence of CRACC, a SLAM family receptor coupled to the adaptor EAT-2, on natural killer cell function

(2009) Mario-Ernesto Cruz-Munoz et al.   NATURE IMMUNOLOGY

Multiple myeloma

(2008) R. A. Kyle et al.   BLOOD

Autologous antitumor activity by NK cells expanded from myeloma patients using GMP-compliant components

(2008) E. Alici et al.   BLOOD

Human natural killer cells

(2008) M. A. Caligiuri   BLOOD

ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype

(2008) A. Soriani et al.   BLOOD

Stem cell factor and interleukin-2/15 combine to enhance MAPK-mediated proliferation of human natural killer cells

(2008) D. M. Benson et al.   BLOOD

Prediction of survival using absolute lymphocyte count for newly diagnosed patients with multiple myeloma: a retrospective study

(2008) Hilmi Ege et al.   BRITISH JOURNAL OF HAEMATOLOGY

Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation

(2008) Jumei Shi et al.   BRITISH JOURNAL OF HAEMATOLOGY

Immunomodulatory drugs Revlimid® (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation

(2008) Dan Zhu et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Histone deacetylase inhibitors sensitize tumour cells for cytotoxic effects of natural killer cells

(2008) Mareike Schmudde et al.   CANCER LETTERS

CS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma

(2008) E. D. Hsi et al.   CLINICAL CANCER RESEARCH

Role of KIRs and KIR ligands in hematopoietic transplantation

(2008) Andrea Velardi   CURRENT OPINION IN IMMUNOLOGY

Soluble and membrane levels of molecules involved in the interaction between clonal plasma cells and the immunological microenvironment in multiple myeloma and their association with the characteristics of the disease

(2008) Martin Perez-Andres et al.   INTERNATIONAL JOURNAL OF CANCER

MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma

(2008) M. Jinushi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Higher Infused Lymphocyte Dose Predicts Higher Lymphocyte Recovery, Which in Turn, Predicts Superior Overall Survival following Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma

(2007) Devendra K. Hiwase et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION